Use of the Mucorales qPCR on blood to screen high-risk hematology patients is associated with better survival
Medical Mycology · 2024
DOI: 10.1093/mmy/myae030 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Mycology, 2024. Verfasst von Anne-Pauline Bellanger und 9 weiteren Autor:innen. Beteiligte Einrichtung: Parasitology-Mycology, University Hospital of Besançon, Besançon, France. Hauptthemen laut MEDLINE: Mucorales, Mucormycosis, Invasive Fungal Infections, Hematology. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Our objective was to determine whether the twice-weekly screening of high-risk hematology patients by Mucorales qPCR on serum affects the prognosis of mucormycosis. Results from all serum Mucorales qPCR tests performed on patients from the hematology unit from January 2017 to December 2022 were analyzed. Patients with positive results were classified as having proven, probable or ‘PCR-only’ mucormycosis. One-month mortality for the local cohort was compared with that of a national cohort of cases of mucormycosis collected by the French surveillance network for invasive fungal disease (‘Réseau de surveillances des infections fongiques invasives en France’ (RESSIF)) from 2012 to 2018. From 2017 to 2022, 7825 serum Mucorales qPCR tests were performed for patients from the hematology unit; 107 patients with at least one positive Mucorales qPCR (164 positive samples) were identified. Sixty patients (70 positive samples, median Cq = 40) had no radiological criteria for mucormycosis and were considered not to have invasive fungal disease (70/7825, 0.9% false positives). It was not possible to classify disease status for six patients (12 positive samples, median Cq = 38). Forty-one patients (82 positive samples, median Cq = 35) had a final diagnosis of mucormycosis. In comparison with the RESSIF cohort, the local cohort was independently associated with a 48% lower one-month all-cause mortality rate (age-, sex-, and primary disease-adjusted hazard ratio = 0.52; 95% confidence interval: 0.29–0.94; P 0.03). Proactive screening for invasive mold diseases in high-risk hematology patients, including twice-weekly Mucorales qPCR on serum, was associated with mucormycosis higher survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Parasitology-Mycology, University Hospital of Besançon, Besançon, France.
- Chrono-Environment UMR CNRS- 6249, University of Franche-Comté, Besançon, France.
- Infection Control Department, University Hospital of Besançon, Besançon, France.
- Hematological Intensive Care Unit, University Hospital of Besançon, Besançon, France.
- Intensive Care Unit, Centre Hospitalier de Versailles, Le Chesnay, France.
- Pharmacy Department, University Hospital of Besançon, Besançon, France.
ORCID-Profile: Anne-Pauline Bellanger, Houssein Gbaguidi-Haore, Laurence Millon
Zitieren
APA
Bellanger, A. P., Gbaguidi-Haore, H., Berceanu, A., Gouzien, L., El Machhour, C., Bichard, D., Lanternier, F., Scherer, E., Millon, L., & French Mycoses Study Group (2024). Use of the Mucorales qPCR on blood to screen high-risk hematology patients is associated with better survival. Medical Mycology. https://doi.org/10.1093/mmy/myae030
Vancouver
Bellanger AP, Gbaguidi-Haore H, Berceanu A, Gouzien L, El Machhour C, Bichard D, et al. Use of the Mucorales qPCR on blood to screen high-risk hematology patients is associated with better survival. Medical Mycology. 2024. doi:10.1093/mmy/myae030
BibTeX
@article{Bellanger2024,
author = {Bellanger, Anne-Pauline and Gbaguidi-Haore, Houssein and Berceanu, Ana and Gouzien, Laura and El Machhour, Chaima and Bichard, Damien and Lanternier, Fanny and Scherer, Emeline and Millon, Laurence and French Mycoses Study Group, French Mycoses Study Group},
title = {Use of the Mucorales qPCR on blood to screen high-risk hematology patients is associated with better survival},
journal = {Medical Mycology},
year = {2024},
doi = {10.1093/mmy/myae030}
}
EUVIMED